Bicara Therapeutics (NASDAQ:BCAX - Get Free Report)'s stock had its "overweight" rating reissued by analysts at Cantor Fitzgerald in a research note issued on Thursday,Benzinga reports. They currently have a $13.01 price target on the stock. Cantor Fitzgerald's price target indicates a potential upside of 0.08% from the stock's current price.
Other analysts have also recently issued reports about the stock. HC Wainwright upped their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, January 27th. Wedbush reaffirmed an "outperform" rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $36.50.
Read Our Latest Report on Bicara Therapeutics
Bicara Therapeutics Stock Performance
BCAX traded down $0.01 during trading hours on Thursday, hitting $13.00. The company's stock had a trading volume of 265,748 shares, compared to its average volume of 426,274. The firm has a 50-day moving average of $13.35. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Spire Wealth Management acquired a new stake in Bicara Therapeutics during the fourth quarter worth about $31,000. BNP Paribas Financial Markets acquired a new stake in Bicara Therapeutics in the fourth quarter valued at approximately $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $33,000. Summit Investment Advisors Inc. purchased a new stake in Bicara Therapeutics in the 4th quarter worth $35,000. Finally, Virtus ETF Advisers LLC acquired a new position in Bicara Therapeutics during the fourth quarter worth $69,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
